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Roberto S Accolla* and Giovanna TosiAbstract
Present immunoprevention and immunotherapeutic approaches against cancer suffer from the limitation of
being not “sterilizing” procedures, as very poor protection against the tumor is obtained. Thus newly conceived
anti-tumor vaccination strategies are urgently needed. In this review we will focus on ways to provide optimal
MHC class II-restricted tumor antigen presentation to CD4+ T helper cells as a crucial parameter to get optimal
and protective adaptive immune response against tumor. Through the description of successful preventive or
therapeutic experimental approaches to vaccinate the host against the tumor we will show that optimal activation
of MHC class II-restricted tumor specific CD4+ T helper cells can be achieved in various ways. Interestingly, the
success in tumor eradication and/or growth arrest generated by classical therapies such as radiotherapy and
chemotherapy in some instances can be re-interpreted on the basis of an adaptive immune response induced by
providing suitable access of tumor-associated antigens to MHC class II molecules. Therefore, focussing on strategies
to generate better and suitable MHC class II–restricted activation of tumor specific CD4+ T helper cells may have
an important impact on fighting and defeating cancer.
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Give me more sky, was the answer
I asked a fish if he were happy
Give me more ocean, was the answer
I asked myself the same question
Give me more birds and more fishes, was the answer
(anonymous african poet)Background
Although the host can mount an immune response
against cancer cells [1] the fact that the tumor takes off
in cancer patients demonstrates that tumor may elude
immune defences [1,2]. Tumors are not simple entities.
They are composed of tumor cells, tumor stroma and
often of a series of blood-derived infiltrating leukocytes
including cells of innate and adaptive immunity [3]. It
has become apparent that tumor-infiltrating leukocytes,* Correspondence: roberto.accolla@uninsubria.it
Department of Surgical and Morphological Sciences, University of Insubria,
Via Ottorino Rossi, n.9, 21100 Varese, Italy
© 2012 Accolla and Tosi; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumincluding neutrophils, macrophages, mast cells, eosino-
phils [4,5] as well as T cells with CD4+/CD25+ pheno-
type and suppressive function on helper and effector T
cells, designated regulatory T cells (Tregs) [6,7], can co-
operate in favouring, instead of antagonizing, tumor
growth. These findings have created a diffuse sentiment
that a sort of pro-tumor polarization of the innate and
adaptive immunity is the cause for tumor cells to sur-
vive, replicate and spread [8,9].
As seen from the side of the protective adaptive im-
mune response, however, the above events can be inter-
preted not as the cause but simply as the consequence
of the tumor strategy to primarily counteract compo-
nents of the acquired immunity (see Table 1). Thus, the
intention here is to re-establish the role of the acquired
immune response (that is: specific antigen presentation,
stimulation of antigen-specific CD4+ T helper (TH) cells
and generation of antigen-specific effector cells) as the
major mechanism of defence against cancer. Instrumental
for this role is to reach optimal MHC class II (MHC-II)-
dependent tumor antigen presentation for triggeringtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Major elements influencing tumor escape
from adaptive immune recognition and destruction
1. Tumor-related
- Insufficient tumor antigen expression
- Loss of MHC class I expression by tumor
- Lack of MHC class II expression by tumor
- Production of immunosuppressive factors for T and B cells
2. Immune cells-related
- Insufficient lymphocyte penetration into the tumor tissue
- Lack of T cell help
Insufficient MHC-II-restricted antigen presentation
Insufficient TH triggering
- Lack or insufficient CTL activity
Insufficient MHC-I-restricted antigen presentation
Insufficient support by TH cells
Scarce lytic activity
- Extrinsic functional blocking of T cells
Regulatory and suppressor cells
Inhibitory cytokines
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cascade of adaptive anti-tumor immunity to counteract
not only tumor onset but also established tumors. These
considerations have important consequences also for the
comprehension of how chemotherapy and/or radiation
therapies may help to block and/or to eradicate the
tumor and for the construction of suitable anti-tumor
vaccine strategies.
Inefficiency of immune effectors in tumor-bearing
hosts
Often immune cells with specificity for tumor-associated
antigens can be found in cancer patients. Due to the jus-
tified belief, based on the groundbreaking studies of Fes-
teinstein [10], that the major mechanism of elimination
of tumor cells should rely on MHC class I (MHC-I)-
restricted CD8+ cytolytic T lymphocytes (CTL), most
tumor immunologists focussed initially their attention
on the presence of CTL in tumor-bearing hosts. Indeed,
CTL can be isolated from tumor tissues, their fine tumor
antigen specificity can be assessed, they can be amplified
in vitro and re-injected into hosts in which, at least in
some experimental animal models, they can inhibit
tumor take or even cure established tumors [11]. On this
basis, clinical trials using CTL-defined antigens as vac-
cines have been performed. However, in most studies
the CTL responses were weak and unable to control
tumor growth and metastasis [12]. This event was due
not only to the frequent loss or reduced expression of
MHC-I molecules in tumor cells [13-15] but also to the
poor tumor specific, MHC-II-restricted T cell helpgenerated in tumor-bearing patients [16], as TH cells are
required for optimal induction of both humoral and cel-
lular effector mechanisms [17] and particularly for CTL
maturation, clonal expansions and acquisition of cyto-
lytic function [18].
TH cell triggering requires recognition of antigenic
peptides presented by MHC-II molecule expressed on
professional antigen presenting cells (APC) including
dendritic cells (DC), macrophages and B cells [19].
Inhibiting and/or avoiding the crucial phase of MHC-II-
dependent tumor antigen presentation to and/or acti-
vation of TH cells would thus be an effective strategy
to block ab origine the adaptive anti-tumor immune
response.
Among the possibilities to explain the insufficient/
absent MHC class II-dependent stimulation of tumor
associated antigen-specific TH cells the following events
have been hypothesized:
1. Tumors elaborate insufficient amounts of
tumor-associated antigens: scarcity of necrotic
and/or apoptotic tumor cells to serve as potential
source of exogenous antigens in fuelling antigen
presentation would hamper the power of presenting
immunologically relevant amounts of TAA to
TH cells, even if APC are functionally available.
2. Tumor cells elaborate products that actively inhibit
the function of APCs: tumor cell may secrete
cytokines and chemokines that are inhibitory
for either antigen uptake, processing or
MHC-II-dependent presentation by APC.
3. Tumor cells may not be suited for acting as surrogate
APC: tumor cells are not classical APCs and they
usually do not express MHC-II molecules. This
prevents their possibility of functioning as surrogate
APC for their putative TAA.
4. Low frequency of TH cells against tumor-associated
antigens: because tumor antigens are mostly self
constituents and very often non mutated products,
the frequency of TH cell precursors specific for
MHC-II-restricted TAA peptides may be very low
and unable to guarantee an efficient effector
function upon antigen stimulation.
Providing optimal MHC-II-restricted tumor
antigen presentation to TH cells: a key parameter
for an efficient anti-tumor immunity
A crucial parameter for TH activation is the optimal
MHC-II-restricted antigen presentation and related anti-
gen processing capable of efficiently triggering tumor-
specific TH cells. Intentionally, we do not specify the
nature of the antigen presenting cells because, as it will
appear later, this role could be played, at least in part, by
the tumor cells themselves. Based on recent results of
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appraisal of historical seminal experiments in immun-
ology, we will underline the notion that providing “more
antigen availability” under the form of optimal MHC-II-
restricted antigen presentation to TH cells is a key
element for generating the cascade of immune effector
functions and polarizing signals that result in tumor re-
jection and acquisition of anti-tumor immune memory.
Fifty years ago Mitchison demonstrated the import-
ance of antigen dose in triggering an adaptive immune
response [20,21] by showing that low amounts of protein
antigen would never trigger an immune response and
might even be tolerogenic. In a recent adaptation of ori-
ginal Mitchison’s paradigm of “more antigen-more re-
sponse” Zinkernagel and coworkers elaborated the
theory that for tumor antigens not only the quantity, but
also the “geographic availability” is a crucial parameter
to instruct the adaptive immune system [22]. If cells of
adaptive immunity do not have the chance to encounter
tumor cells because the tumor remains localized at sites
out of contact with immune cells, than the tumor will be
neglected, “ignored” by the immune system.
Optimal MHC-II-restricted antigen presentation to
TH cells in preventive anti-tumor vaccination: the
example of CIITA-induced MHC class II expression
in tumor cells
In the recent past, many attempts have been made to
construct preventive anti-tumor vaccines by using as a
primary source of antigen whole tumor cells treated by
different procedures to make them more immunogenic.
Irradiated or genetically modified tumor cells have been
used even in clinical trials [23].
As a different approach to obtain optimal triggering of
the adaptive anti-tumor immune response, a vaccination
strategy with tumor cells transduced with the AIR-1-
encoded MHC-II transactivator CIITA [24,25] has been
explored in our laboratory. The rationale underlying this
approach was that CIITA-transfected tumor cells may
act as “surrogate APC” via MHC-II-restricted tumor-
associated antigen presentation to tumor-specific TH
cells for their optimal triggering.
Indeed, beside controlling MHC-II gene expression,
CIITA acts on other crucial steps of the antigen proces-
sing and presentation mechanism, via upregulation of
Invariant chain [26] and DM [27] expression. Moreover,
crucial to this approach were the assumptions, verified
by previous elegant studies, that endogenous proteins
(as most tumor antigens are) could access the MHC
class II pathway of antigen presentation [28,29] and that
peptides of these proteins could be recognized and serve
as immunogen for TH cell triggering [30,31].
Our studies have demonstrated that efficient rejection
of CIITA-transfected tumor cells of distinct histologicalorigin can be achieved in high percentage of injected im-
munocompetent syngeneic mice [26,32,33]. Importantly,
CIITA-tumor vaccinated mice develop an anamnestic
response allowing them to reject parental tumors very
efficiently [26,32,33]. That CIITA-dependent MHC class
II expression in tumor cells was instrumental to trigger
a protective immune response against the parental
tumor was also demonstrated by vaccination experi-
ments with non replicating CIITA-transfected tumor
cells [34]. The immunological basis of tumor rejection
upon vaccination with CIITA-transfected tumor cells
was extensively investigated. Rejection and/or reduced
tumor growth were mediated by tumor specific CD4+
TH and CD8+ CTL [26,32-34]. Importantly, tumor-
specific primed TH cells were long-living memory cells
and they could adoptively transfer resistance to tumor
growth even after many months from original stimula-
tion [33], implying the stabilization of a protective
phenotype of effector cells over time.
The comparative study of the tumor microenviron-
ment and of tumor draining lymph nodes in mice
injected with parental or with CIITA-transfected tumor
cells provided critical insight on the mechanisms trig-
gered by CIITA-transfected tumor cells and their pos-
sible role as surrogate APCs [32]. Tumors derived from
parental cells presented scarce infiltrate, represented
mainly by macrophages and neutrophils, very few CD4+
T cells, absence of DC and CD8+ T cells. In contrast the
site of CIITA-transfected tumor cells injection was rap-
idly infiltrated by CD4+ T cells. This was followed, days
later, by the appearance of DC and CD8+ T cells and,
immediately after, by the generation of extensive areas of
tumor cell necrosis. The fact that CD4+ T cells colonized
CIITA-tumor tissue before CD8+ T cells and DC, along
with the capacity of CIITA-expressing tumor cells to
process and present antigenic peptides to CD4+ T cells
in vitro [32,35], supports the hypothesis that much of
the tumor-specific TH cell triggering and/or restimula-
tion takes place in the tumor tissue itself and is directly
mediated by tumor cell-derived MHC class II molecules,
as previously suggested [36-38].
Interestingly, mice rejecting CIITA-tumors and mice
vaccinated with CIITA-tumor cells rejecting a challenge
with parental tumors displayed a polarized CD4+ TH1
cell phenotype in their tumor-draining lymph nodes, as
compared to TH2-like cells found in parental tumor-
bearing mice. Moreover, the fact that CIITA-transfected
tumor cells could trigger a potent anamnestic and per-
sistent anti-tumor T cell response without an apparent
sequel of autoimmunity, suggests that most of the anti-
tumor response was directed against tumor- and not
self-derived antigens.
The success of this approach underscores the importance
of the optimal MHC-II-restricted antigen presentation,
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of tumor antigens and renders unnecessary to know a
priori the nature, the identity and the immunogenic hier-
archy of the tumor-associated antigen(s). It is of relevance
that the idea of increasing the density of tumor antigen
displayed by MHC-II molecules, as it results from our ap-
proach of rendering tumor cells MHC-II positive by stable
expression of CIITA, has been pursued also by other
approaches based, for example, on providing sustained
antigenic epitope in endosomal compartments by con-
structing Invariant chain-antigenic epitope chimeras
[39-41] or by treating tumor cells with epigenetic modi-
fiers that increase the expression of tumor-specific shared
antigens [42,43].
Optimal MHC-II-restricted antigen presentation
to TH cells in anti-tumor therapy: the example
of L19-TNFα conjugate in therapy-induced
anti-tumor vaccination
In collaboration with Luciano Zardi, Laura Borsi and their
team we have conducted experiments of tumor therapy in
animal models by using mouse TNFα (mTNFα) covalently
bound to a Fv antibody (L19) specific for the beta form of
Fibronectin, selectively expressed in tumor neovasculature
[44]. Injection of L19mTNFα conjugate induces a dra-
matic necrosis of established tumors as it allows concen-
trating therapeutically active doses of TNFα at the tumor
level. When combined with the cytostatic drug melphalan,
this treatment dramatically potentiated the effect of mel-
phalan at the tumor site.
Two crucial observations, related to the importance of
the adaptive immune response against the tumor in this
approach, were made. First, the treatment resulted in a
high rate of complete, long-lasting tumor eradication in
distinct tumor models without any apparent adverse side
effects and with no recurrence. Second, tumor-bearing
immunodeficient SCID mice did not respond well to the
L19mTNFα treatment even when combined with mel-
phalan [45]. This prompted us to analyze whether the
cured mice developed a tumor-specific immunity. In-
deed, all cured mice were resistant to tumor challenge
and the tumor rejection was mediated by CTL and, par-
ticularly, by long-living, tumor specific CD4+ TH cells
[45]. TH cells were crucial for the establishment of
what we defined as “therapy induced anti-tumor vaccin-
ation” because naive mice depleted of CD4+ TH cells
were unable to reject primary tumors after L19mTNFα/
melphalan treatment [46]. Moreover, CD4+ TH cells
derived from cured animals treated with L19mTNFα/
melphalan, while fully competent in generating tumor
rejection when adoptively transferred together with
tumor cells in naive mice, were incapable of inducing
tumor rejection in CD8-depleted naïve animals, strongly
suggesting that a major protective role of primed anti-tumor CD4+ T cells lies in triggering CD8+ naive T cells
to become functionally mature antitumor CTL effectors
[46]. Taken together, these findings strongly indicate that
the L19mTNFα/melphalan treatment was instrumental
in generating optimal MHC-II-restricted tumor antigen
presentation to efficiently trigger tumor specific TH cells
which, in turn, triggered naïve CTL precursors and sus-
tained their cytolytic anti-tumor effector function.
Histological characterization of the tumor tissue evi-
denced, early after treatment, distinctive areas of necrosis
with infiltration, mainly, of granulocytes and macro-
phages. One week after L19mTNFα/melphalan treatment
a remarkable increase in the number of CD4+ and CD8+
T cells infiltrating the tumor was observed as compared
to tumors from untreated animals. This was accompan-
ied by a dramatic increase in granulocyte infiltration, to a
lesser extent of macrophages and by the extension of
areas of tumor necrosis [46]. Thus, the tumor necrosis
induced by L19mTNFα/melphalan and the earlier infil-
tration of granulocytes contributing to tumor cell killing
could be the key element to provide sufficient amount of
tumor antigens for fuelling professional APC, which
could then stimulate specific anti-tumor CD4+ TH cells
and CD8+ effector CTL, leading to the complete rejec-
tion of the tumor and to the establishment of a critical
reservoir of memory effector cells responsible for the
accelerated rejection of the tumor upon challenge.
Further phenotypic and functional characterization of
the CD4+ T cells involved in the priming of the anti-
tumor immune response following therapeutic treatment
revealed that while untreated tumor-bearing mice had in
their spleen and tumor-draining lymph nodes IL-4-
secreting TH2-type cells, treated mice displayed a mixed
TH1- and TH2-type of response with a great percentage
of cells secreting IFNγ [46,47]. Thus, as it was shown for
the preventive vaccination approach with CIITA-
expressing tumor cells, a rapid appearance and conver-
sion, although not exclusive, toward a TH1 immune
phenotype was associated with the protective adaptive
anti-tumor response generated by the treatment with
L19mTNFα and melphalan.
All together the experimental evidences gathered from
our approaches of either preventive or therapy–induced
anti-tumor vaccination clearly demonstrate that a sub-
version toward an anti-tumor microenvironment can be
generated by promoting optimal MHC-II-restricted anti-
gen presentation to TH cells not only before the tumor
onset but also after cancer has developed (Figure 1).
Radiotherapy and chemotherapy as procedures to
potentially induce optimal MHC-II-restricted
antigen presentation to TH cells
To the light of these findings and in consideration that
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Figure 1 Optimal MHC-II-restricted tumor antigen presentation as a key parameter for an effective anti-tumor adaptive immune
response. Optimal MHC-II-restricted tumor antigen presentation may result from either surrogate antigen presenting activity by tumor
cells expressing CIITA-dependent MHC class II (MHC-II) molecules or by increasing the amount of tumor antigen availability for classical
antigen-presenting cells (APC) via therapeutical approaches resulting in immunogenic cell death, such as radiotherapy (RT), chemotherapy, and
biotherapy with, for example, L19-TNFα and melphalan (L19-TNFα + Melphalan). Optimal MHC-II-restricted tumor antigen presentation generated
by the two approaches is instrumental for the optimal triggering of anti-tumor CD4+ T helper cells (TH). These MHC-II-restricted anti-tumor TH
cells have a dual action in the process of immune-mediated tumor rejection: a) they are required for the activation, proliferation and cytolytic
activity of CD8+ anti-tumor cytotoxic T lymphocytes (CTL); b) they are major players in the subversion of the tumor microenvironment toward an
anti-tumor milieu by polarizing, for example, the lymphocyte infiltrate toward a mixed TH1/TH2 or exclusive TH1 population with an increased
frequency of IFNγ secreting cells, by favouring the recruitment of inflammatory cells such as polymorphonuclear cells, by inhibiting the function
and/or the recruitment of leukocytes with suppressive action on TH cells and on tumor-specific CTL.
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series of previously published data on the appearance of
an anti-tumor immune response following conventional
anti-tumor therapy, may be re-interpreted also as a way
to offer sufficient amounts of MHC-bound tumor anti-
gens to the adaptive immune system.
For example, radiation therapy (RT) particularly when
localized to the tumor mass, given alone [48] or in com-
bination with immunostimulatory cytokines (IL-2 and
TNFα) [49,50] enhances its efficacy by generating anti-
tumor specific CTL responses. RT can also increase CTL
stimulation by up-regulating MHC class I expression in
tumor cells [51,52] and, more interestingly, by positively
influencing antigen processing and presentation by den-
dritic cells [53].
Chemotherapy can also increase the immunogenicity
of tumor cells which are recognized by immune effectors
[54]. Central to this role of RT and Chemotherapy is the
concept of immunogenic cell death that, provoked by
the therapeutical agent, finally ends up in the triggering
of an adaptive immune response [55], a concept that canbe easily accommodated within the frame of the optimal
MHC-II-restricted antigen presentation to TH cells
described here (Figure 1).
We firmly believe that re-interpretation of the avail-
able data on the several ways through which preventive
and therapeutic approaches to fight cancer may result in
the generation of a protective adaptive immune response
against the tumor will lead to the careful consideration
that a crucial parameter underlying this effect is indeed
the better availability of tumor antigens offered for rec-
ognition by tumor-specific TH via an optimal MHC-II
restricted antigen presentation. This will possibly help to
better understand the initial phases of the immune re-
sponse against tumors and offer potential new strategies
to prevent and fight cancer.
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